Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Says It May Buy Back $30M of Stock

NEW YORK, Oct. 14 - Incyte Genomics today said it may spend up to $30 million to buy back its own stock, which it says is undervalued.


The company said its shares "represent an attractive investment opportunity," and it might buy some of them back in the open market or in private transactions.


Shares in Incyte were up 14 cents, or 4.4 percent, at $3.29 on the Nasdaq exchange.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.